Phillip Securities Group
Please note that the Day Light Saving of Europe and US will be effective on April 1st and March 11th respectively. The trading hours for those relevant contracts will be 1 hour earlier. Any questions, please contact us at 22776677.For details, please visit our foreign futures website or contact us at 22776677.Moreover,the spread of USD/JPY is low as one pip.Please click here for details
 
  Phillip Investor Notes

19-04-2024(Fri) 18-04-2024(Thu) 17-04-2024(Wed) 16-04-2024(Tue) 15-04-2024(Mon)
Page : 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments ¤¤¤åª©
22 Feb, 2017 (Wednesday)

            
CALC(1848)
Analysis¡G
China Aircraft Leasing Group (1848) has recently issued a positive profit alert. The consolidated profit attributable to shareholders for the year ended 31 December 2016 is expected to increase by not less than 60% as compared with that of the year ended 31 December 2015. Based on the net profit of HK$380 million for FY2015, its FY2016 net profit will not be less than HK$608 million. (I do not hold the above stock)
Strategy¡G
Buy-in Price: $9.50, Target Price: $10.70, Cut Loss Price: $8.90

Humanwell Healthcare(600079)
Analysis¡G
Humanwell Healthcare realized revenues of RMB 8.78 billion in the first three quarters, a YoY increase of 26.6%. Net profit attributable to shareholders of parent company stood at RMB 620 million, up by 41.2% over the previous year, which was mainly attributed to the consolidation of EPIC Pharm. After EPIC net profit, acquisition costs and new financial expenses are excluded, the adjusted net profit attributable to shareholders of parent company reached RMB 470 million, increasing by 13.6% year-on-year and meeting the company`s expectation of about 15% of endogenous growth rate. After successfully acquiring EPIC Pharmaceuticals, Inc. and obtaining the U.S. license for narcotics control and production lines, Humanwell Healthcare started to make major breakthroughs in overseas layout. In the meantime, thanks to the increased sales volume of patented dermatologic medicines and the rise in the profitability of soft capsule orders, the company`s international outlook is optimistic. What`s more, the company announced that it intends to make a non-public offering of stocks to its major shareholder Wuhan Modern Technology with an issue price of RMB 17.76/share. The raised funds will not exceed RMB 2.8 billion. The fund-raising will improve the company`s financial structure, reducing the liability/asset ratio to about 55% and easing financial pressures with the financial costs expected to reduce by more than RMB 100 million.
Strategy¡G
Buy-in Price: CNY19.12, Target Price: CNY23.00, Cut Loss Price: CNY17.60


Geely (175.HK) - Jan sales review

Strong Momentum Continues in January

Geely Automobile released its sales volume for January of 2017: The total sales volume soared by 71% yoy to 103,000 vehicles. Among them, the domestic sales volume soared by 75% yoy to 102,000 vehicles, accounting for a larger proportion of 99.03% of the total sales volume, while the export volume reached 994 vehicles, fell by 51% yoy. Geely's sales growth rate was much higher than the industry average and also higher than its several major industry counterparts.

Compared with the 60,000-odd-vehicle sales in the same period last year, the growth in January mainly owes to the sales of several new SUVs, with the sales of Boyue, Vision SUV and Emgrand GS amounting to 20,147, 10,226, and 10,333 vehicles, respectively. In addition, the robust sale of sedans of the new Emgrand, Vision and Emgrand GL contributed to the overall growth with 26,314, 14,716 and 10,208 vehicles, respectively.

The 2017 Target May be Outperformed Again

As noted in the 2017 sales target guidelines provided by the company's management, the annual sales will increase by 30% to 1 million vehicles. We therefore anticipate according to the current sales momentum that the company is very likely to exceed its target again with the annual growth rate rising to 50%. The reasons are as follows:

1) The main models have maintained robust sales. Last year, the demand of several popular models exceeded supply, and it will take at least several months to handle the order backlog.

2) The CMA platform, a product line which the company co-established with Volvo, will launch three new models under the brand-new high-end brand LYNK & CO this year, including a compact, slightly smaller SUV than Boyue in size, a sedan and a crossover model. It is expected that their selling prices will continue to climb.

Investment Thesis

We believe the new brand's release marks the official launch of Geely Automobile's advancing strategy, and the follow-up brand management and operation will bring both challenges and opportunities to the company. As the positive effect of acquiring Volvo began to emerge, Geely Auto's overall strength has been elevated to a new high. We are optimistic about its steady growth in medium and long term sales.

Considering the better-than-expected Jan sales we lift our forecast EPS and therefore we raise the target price to HK$ 13.35, equivalent to 13.2x/9.5 estimated P/E ratio of 2017/2018. (Closing price as at 20 Feb 2017)

Financials

Click Here for PDF format...




Recommendation on 22-2-2017
RecommendationAccumulate
Price on Recommendation Date$ 11.140
Suggested purchase priceN/A
Target Price$ 13.350
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+ 86 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Phillip Research - Hong Kong ½÷¥ß¬ã¨s³¡ ¡V ­»´ä¤Î¤¤°ê
Company Stock Code Last Update Suggestion Target Price Price on Recom
Information Techology Research Department N/A+852 2277 6527research@phillip.com.hk
O-Net Technologies87727/09/2016No Rating4.02
O-Net communications87726/10/2010BUY7.156
Transportation and Automobiles Zhang Jing (86) 2151699200-103zhangjing@phillip.com.cn
Geely17522/02/2017Accumulate13.350.000
GWM233315/02/2017Accumulate9.678.87
Insurance Research Department (86) 21 51699400-110research@phillip.com.cn
Media & Publishing Research Department (+ 86 21 51699400-107)research@phillip.com.cn
Wisdom Sports Group166111/07/2016Buy3.32.18
NetDragon77716/06/2016Buy28.422.9
Pharmaceutical Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Yibai Pharmaceutical60059417/02/2017Accumulate19.516.39
Salubris002294.CH10/02/2017BUY36.729.04
Industrial Goods Ocean Pan +852 2277 6515oceanpan@phillip.com.hk
TK Group228310/01/2017Buy2.82.18
Health & Personal Care Fan Guohe  (+ 86 21 51699400-110)fanguohe@phillip.com.cn
Harmonicare150917/01/2017Buy5.534.45
Guangzhou Baiyunshan Pharma87418/10/2016Buy24.4819.16
New Energy Wang Yannan 86 21 51699400-107wangyannan@phillip.com.cn
CONCORD NE18224/10/2016Buy0.60.39
SINGYES SOLA75014/10/2016Buy5.14.12
Food, Beverage and Retail Research Department (86) 21 51699400-110research@phillip.com.cn
Haier Elec116921/02/2017Accumulate15.9314.4
Koradior370914/02/2017Buy11.689.01
Telecommunications Fan Guohe + (86) 21 51699400-110fanguohe@phillip.com.cn
Chinasoft International35426/10/2016Buy4.863.72
Chinasoft International35425/10/2016Buy4.863.72
Mainland Property John Wong +852 2277 6527johnycwong@phillip.com.hk
Longfor Properties96009/02/2017Buy12.811.24
Kerry Properties68302/02/2017Buy26.422.05
Utilities Tim Wong +852 2277 6516timwong@phillip.com.hk
Jiangnan Water60119920/02/2017Buy10.57.92
BOW300070.SZ13/02/2017Buy19.215.92
Properties John Wong +852 2277 6527johnycwong@phillip.com.hk
Hopewell Holdings5416/02/2017Neutral27.727.5
LESSO212823/09/2015Buy7.96.02
Software & Service Research Department (86) 21 51699400-110research@phillip.com.cn
Goldpac Group331518/02/2015N/A4.77
IGG800221/11/2014Accumulate3.953.44
Hotels and Entertainment John Wong (+ 852 2277 6527)johnycwong@phillip.com.hk
Hongkong & Shanghai Hotels4505/01/2017Accumulate9.78.46
Great Eagle Holdings Ltd4129/12/2016Accumulate38.633.65

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the ¡§Group¡¨) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products¡¦ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

ª©Åv©Ò¦³¡A ½¦L¥²¨s¡C

Copyright(C) 2017 Phillip Securities (HK) Ltd. All Rights Reserved.


Copyright © 2011 Phillip Securities Group. All Rights Reserved [ Risk Disclosures Statement ] [ Terms and Conditions ] [ Personal Data Policy ]